Article
Intestinal organoids for Cystic Fibrosis research
28 Nov 2019
Abstract excerpt
Significant progress has been made in the development of CFTR modulator therapy; however, current CFTR modulator therapies are only available for a minority of the CF-patient population. Additionally, heterogeneity in in vivo modulator response has been reported among individuals carrying homozygous F508del-CFTR, adding to the desire for an optimal prediction of response-to-therapy on an individual level. In the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
